Gefitinib in Non Small Cell Lung Cancer

Gefitinib is an oral, reversible, tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) that plays a key role in the biology of non small cell lung cancer (NSCLC). Phase I studies indicated that the recommended dose of gefitinib was 250 mg/day. Rash, diarrhea, and nausea were the most...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BioMed research international 2011-01, Vol.2011 (2011), p.1-14
Hauptverfasser:	Sandomenico, Claudia, Piccirillo, Maria Carmela, Costanzo, Raffaele, Carillio, Guido, Montanino, Agnese, Daniele, Gennaro, Giordano, Pasqualina, Bryce, Jane, De Feo, Gianfranco, Di Maio, Massimo, Rocco, Gaetano, Normanno, Nicola, Perrone, Francesco, Morabito, Alessandro
Format:	Artikel
Sprache:	eng
Schlagworte:	Acne Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Cancer Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Care and treatment Chemotherapy Clinical medicine Clinical trials Development and progression Diarrhea Drug therapy ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics ErbB Receptors - therapeutic use Feasibility studies Gefitinib Health aspects Humans Lung cancer Lung cancer, Non-small cell Lung Neoplasms - drug therapy Mutation Physiological aspects Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Proteins Quinazolines - adverse effects Quinazolines - therapeutic use Radiation therapy Review Thoracic surgery Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!